## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT C	OF CHANGES IN	I BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* UECKER DARRIN				2. Issuer Name <b>and</b> Ticker or Trading Symbol Pulse Biosciences, Inc. [ PLSE ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
UECK	EK DAKI	XIIV			$I^{-}$						-			Directo	r		10% Ov	vner
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/12/2023							Officer below)	(give title		Other (s below)	pecify	
C/O PUI	LSE BIOSC	IENCES, INC.			1077	12/2	2023							Chi	ief Techn	ology	Officer	
3957 POINT EDEN WAY					4. If							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	.RD C.	A	94545												led by Mor	•	orting Person	
(City)	(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication																	
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Tal	ole I - Nor	ı-Deriv	ative/	e Se	curities	s Ac	quired, D	ispos	sed c	of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transar Date (Month/Date				Execution Date,		Transaction Disposed (Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
								Code	V A	Amount	(A) (D)	(A) or (D) Price		etion(s) and 4)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	xercise (Month/Day/Year) if any Code (Instr e of vative (Month/Day/Year) 8)						ies g Security	8. Price of Derivative Security (Instr. 5)			Beneficial Ownership (Instr. 4)						
				C	ode	v	(A)	(D)	Date Exercisable	Expir Date	ration	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Option (right to buy)	\$7.08	07/12/2023			A		200,000		(1)	07/12	2/2033	Common Stock	200,000	(2)	200,000		D	

## **Explanation of Responses:**

- 1. The option was granted on July 12, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to two tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds \$4 billion, in both cases, subject to the Reporting Person's continued service through each vesting milestone.
- 2. Not applicable.

/s/ Kenneth B. Stratton, as Attorney-in-Fact

07/14/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.